Inozyme Pharma (INZY)
(Delayed Data from NSDQ)
$4.82 USD
+0.13 (2.77%)
Updated May 31, 2024 04:00 PM ET
After-Market: $4.82 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth F Momentum F VGM
Brokerage Reports
0 items in cart
Inozyme Pharma, Inc. [INZY]
Reports for Purchase
Showing records 41 - 60 ( 71 total )
Company: Inozyme Pharma, Inc.
Industry: Medical - Biomedical and Genetics
INZ-701 on Track for Near-term Readouts in ENPP1 and ABCC6 Deficiency
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Inozyme Pharma, Inc.
Industry: Medical - Biomedical and Genetics
2Q22 Results; Top-Line Data Expected For INZ-701 in ENPP1 Deficiency in 4Q22, and in ABCC6 Deficiency in 1Q23
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Inozyme Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Company: Inozyme Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Preliminary Data From Phase 1/2 Trial of INZ-701 in ABCC6 Deficiency
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Inozyme Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Company: Inozyme Pharma, Inc.
Industry: Medical - Biomedical and Genetics
1Q22 Results; Preliminary Data for ABCC6 Deficiency Trial Expected 2Q22; Top-Line Data for Phase 1/2 ENPP1 Study in 2H22
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Inozyme Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Company: Inozyme Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Update on Phase 1/2 Trials in ABCC6 Deficiency and ENPP1 Deficiency
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Inozyme Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Positive Preliminary Data Reported From Phase 1/2 Study of INZ-701 in ENPP1 Deficiency Patients
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Inozyme Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Company: Inozyme Pharma, Inc.
Industry: Medical - Biomedical and Genetics
4Q21 Results; Preliminary Safety and Biomarker Data From Phase 1/2 Trial in ENPP1 Deficiency in 1H22
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Inozyme Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Pyrophosphate Savings Time with INZ-701 Data Around the Corner
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Inozyme Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Company: Inozyme Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Company: Inozyme Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Company: Inozyme Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Company: Inozyme Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Company: Inozyme Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Company: Inozyme Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Natural History Confirms ENPP1 Morbidity and Pre-Clinical Gene Therapy Data
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D